Cutaneous B-cell lymphomas: Update on diagnosis, risk-stratification, and management

IF 3.2 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Presse Medicale Pub Date : 2022-03-01 DOI:10.1016/j.lpm.2022.104109

Paolo Fava , Gabriele Roccuzzo , Silvia Alberti-Violetti , Vieri Grandi , Alessandro Pileri , Nicola Pimpinelli , Emilio Berti , Pietro Quaglino

{"title":"Cutaneous B-cell lymphomas: Update on diagnosis, risk-stratification, and management","authors":"Paolo Fava , Gabriele Roccuzzo , Silvia Alberti-Violetti , Vieri Grandi , Alessandro Pileri , Nicola Pimpinelli , Emilio Berti , Pietro Quaglino","doi":"10.1016/j.lpm.2022.104109","DOIUrl":null,"url":null,"abstract":"<div><p><span>PCBCLs are a group of Non-Hodgkin's B-cell lymphomas originating in and usually confined to the skin, representing approximately one fourth of primary cutaneous lymphomas<span> (PCL). Their current classification system has been the result of the joint World Health Organization (WHO) - European Organization for Research and Treatment of Cancer (EORTC) consensus in 2018. To date, several types of PCBCLs have been described in the scientific literature, with different clinical presentation and prognosis. Primary cutaneous follicle-center lymphoma (PCFCL) and primary cutaneous </span></span>marginal zone lymphoma (PCMZL) are the most common forms, with a typical indolent course. On the contrary, primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT) is less common, yet more aggressive, with a reported 5-year overall survival of approximatively 50%. In this review, we outline the PCBCLs defining diagnostic criteria, report the features of the less common subtypes and summarize the noteworthy therapeutical options currently available in this field.</p></div>","PeriodicalId":20530,"journal":{"name":"Presse Medicale","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Presse Medicale","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0755498222000021","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 8

Abstract

PCBCLs are a group of Non-Hodgkin's B-cell lymphomas originating in and usually confined to the skin, representing approximately one fourth of primary cutaneous lymphomas (PCL). Their current classification system has been the result of the joint World Health Organization (WHO) - European Organization for Research and Treatment of Cancer (EORTC) consensus in 2018. To date, several types of PCBCLs have been described in the scientific literature, with different clinical presentation and prognosis. Primary cutaneous follicle-center lymphoma (PCFCL) and primary cutaneous marginal zone lymphoma (PCMZL) are the most common forms, with a typical indolent course. On the contrary, primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT) is less common, yet more aggressive, with a reported 5-year overall survival of approximatively 50%. In this review, we outline the PCBCLs defining diagnostic criteria, report the features of the less common subtypes and summarize the noteworthy therapeutical options currently available in this field.

查看原文本刊更多论文

皮肤b细胞淋巴瘤:诊断、风险分层和管理的最新进展

pcbcl是一组起源于皮肤且通常局限于皮肤的非霍奇金b细胞淋巴瘤，约占原发性皮肤淋巴瘤(PCL)的四分之一。他们目前的分类系统是世界卫生组织(世卫组织)和欧洲癌症研究和治疗组织(EORTC)在2018年达成共识的结果。迄今为止，在科学文献中已经描述了几种类型的多氯联苯氯化合物，具有不同的临床表现和预后。原发性皮肤滤泡中心淋巴瘤(PCFCL)和原发性皮肤边缘区淋巴瘤(PCMZL)是最常见的形式，具有典型的惰性病程。相反，原发性皮肤弥漫性大b细胞淋巴瘤，腿型(PCDLBCL, LT)不太常见，但更具侵袭性，据报道5年总生存率约为50%。在这篇综述中，我们概述了多氯联苯cls的诊断标准，报告了不常见亚型的特征，并总结了目前该领域值得注意的治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Presse Medicale 医学-医学：内科

自引率

3.70%

发文量

审稿时长

43 days

期刊介绍： Seule revue médicale "généraliste" de haut niveau, La Presse Médicale est l''équivalent francophone des grandes revues anglosaxonnes de publication et de formation continue. A raison d''un numéro par mois, La Presse Médicale vous offre une double approche éditoriale : - des publications originales (articles originaux, revues systématiques, cas cliniques) soumises à double expertise, portant sur les avancées médicales les plus récentes ; - une partie orientée vers la FMC, vous propose une mise à jour permanente et de haut niveau de vos connaissances, sous forme de dossiers thématiques et de mises au point dans les principales spécialités médicales, pour vous aider à optimiser votre formation.